CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
CTS Dallas and Phoenix Labs successfully implemented WNV NAT testing on the Panther Testing Platform...
On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Ris...
The recent communication regarding the recent Anti-SARS-CoV-2 Total assay in Tampa has brought about...
We are very excited to launch our new website! Please take a few moments to click around and explore...
Daylight Saving Time Begins March 10, 2019. As a friendly reminder, airlines often change their rout...
We sincerely hope to see you at this year’s AABB Annual Meeting in Boston, MA on October 12-16...